SCHOFIELD, Wis., Nov. 29, 2013 /PRNewswire/ -- PuraMed
BioScience®, Inc., (OTCBB:PMBS), a researcher,
developer, and marketer of over-the-counter (OTC) medicinal and
healthcare products, announced today that its product,
LipiGesic® M does not contain caffeine, acetaminophen,
or aspirin. It is the only clinically tested, non-prescription
migraine medication available on retail shelves today that has
shown no evidence of rebound or "medication overuse headache" as a
reported side effect.
In the article entitled, "Choosing Wisely in Headache
Medicine: The American Headache Society's List of Five Things
Physicians and Patients Should Question," the authors warn
physicians not to "recommend prolonged or frequent use of
over-the-counter (OTC) pain medications for headache." The American
Headache Society (AHS) article recommended that OTC headache
pain relievers should not be used more than twice a week to avoid
the incidence of "medication overuse headache," especially when the
medications contain caffeine. The article goes on to cite the
dangers of liver damage caused by the overuse of acetaminophen and
gastrointestinal bleeding caused by overuse of nonsteroidal
anti-inflammatory drugs.
"Having a product like LipiGesic M that does not produce
'medication overuse headache' is important in light of the latest
report published by the AHS," said Russell
Mitchell, CEO of PuraMed BioScience. "There have been no
reported occurrences of LipiGesic M causing a rebound headache no
matter how frequently a person uses it. LipiGesic M's patented
formulation of feverfew and ginger also has not been shown to cause
liver damage, stomach bleeding, or other adverse side effects."
When writing the "Choosing Wisely in Headache Medicine:
..." article published in the November/December 2013 issue of Headache, the
authors asked AHS members to suggest tests, procedures, or
treatments in headache medicine that were commonly overused or
misused. The five suggestions selected "were associated with poor
patient outcomes, low value care or documented overuse or misuse,"
the study said.
"LipiGesic M is not like the pain relievers that are cited in
the study," said Mitchell. "Based on the results of our clinical
trial, LipiGesic M performs more like a prescription migraine
medication than an OTC migraine formulation, but without the
unwanted side effects associated with either product category."
This fact was also stated in Advances in Drug Development for
Acute Migraine, an article published in Drugs medical
journal in December 2012. Speaking of
LipiGesic M, the authors, including headache expert Dr.
Roger Cady, said, "Advantages of
this product include lower cost, OTC availability, and it is not
likely to produce medication overuse headache. It is an excellent
first-line therapy for very early intervention, as it is compatible
with all other acute treatment options."
The Cleveland Clinic website also lists many medications that
can cause rebound headache. The list includes: "aspirin, sinus
relief medications, acetaminophen, nonsteroidal anti-inflammatory
medications (NSAIDs), sedatives for sleep, codeine and prescription
narcotics, and over-the-counter combination headache remedies
containing caffeine (such as Anacin®,
Excedrin®, Bayer Select®, and others)."
http://my.clevelandclinic.org/disorders/Headaches/hic_Rebound_Headaches.aspx
"Recently there have been an increased number of Food and Drug
Administration safety warnings associated with acetaminophen and
other OTC pain medications," said Mitchell. "People forget that
many OTC medications were only available as prescriptions when they
were first introduced. That's why it is personally gratifying to
offer a highly effective treatment for acute migraine that does not
cause the harmful side effects mentioned by the report."
Currently, PuraMed BioScience has 68,702,155 shares
outstanding.
About PuraMed BioScience, Inc.:
PuraMed BioScience has completed a double blind placebo clinical
trial for its leading product, LipiGesic® M, a
sublingual acute treatment for the relief from migraine headaches,
which was published in the top-tier medical journal, Headache.
http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.
LipiGesic® M has national distribution and is available
nationwide in some of the largest chain drug stores in the United States.
Forward-Looking Statements:
This news release contains forward-looking statements regarding
PuraMed BioScience, Inc., and its future business plans, which
statements involve known and unknown risks and uncertainties. Such
risks and uncertainties may cause actual results and future
achievements of PuraMed BioScience to be materially different than
those implied by these forward-looking statements. PuraMed
BioScience has and undertakes no obligation to provide public
updates and revisions to these forward-looking statements to
reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Patricia McMurtrie
715-571-4910
patricia@PuramedBioScience.com
www.PuramedBioScience.com
SOURCE PuraMed BioScience, Inc.